Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook

Thelansis’s “Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chemotherapy-Induced Peripheral Neuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview

Chemotherapy-induced peripheral neuropathy (CIPN) stands out as a prevalent adverse effect triggered by antineoplastic medications, with its occurrence ranging from 19% to over 85%. It primarily manifests as sensory nerve damage, accompanied by varying degrees and durations of motor and autonomic alterations. Given its high occurrence among cancer patients, CIPN poses a significant challenge for patients, survivors, and their healthcare providers. This is primarily due to the absence of a single effective method to prevent CIPN. Central sensitization is pivotal in neuropathic pain, especially from nerve damage. The harm to peripheral nerves, particularly C-fibers, results in spontaneous activity that disrupts secondary neurons in the spinal dorsal horn, leading to heightened excitability due to various molecular changes. Clinically, CIPN manifests as sensory, motor, and autonomic deficits of varying severity. Sensory symptoms usually initiate the condition, typically affecting the hands and feet and resembling a classic "glove and stocking" neuropathy, with the most distal parts of the limbs exhibiting the most pronounced deficits. These symptoms encompass numbness, tingling, altered touch sensation, impaired vibration perception, paresthesias, and discomfort triggered by contact with warm or cold surfaces. Several predisposing risk factors for CIPN have been identified, including patient age (higher risk in older individuals), pre-existing neuropathy before chemotherapy (e.g., diabetic neuropathy), a history of smoking, impaired kidney function with reduced creatinine clearance, exposure to other neurotoxic chemotherapy agents, the presence of paraneoplastic antibodies, and direct neuropathy associated with the cancer itself.

• The prevalence of CIPN varies depending on the chemotherapy agent used, with reported rates ranging from 19% to more than 85%. It is most prominent in the case of platinum-based drugs (70–100%), taxanes (11–87%), thalidomide and its derivatives (20–60%), and ixabepilone (60–65%).
• According to Thelansis, the incidence of chemotherapy-induced peripheral neuropathy (CIPN) in the G8 countries is estimated to range from 3.2 million cases in 2020 to 3.5 million by 2030.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: